Modality
Peptide
MOA
VEGFi
Target
KRASG12C
Pathway
RAS/MAPK
Bladder Ca
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ May 2030
Phase 1Current
NCT06751063
940 pts·Bladder Ca
2018-08→2030-05·Not yet recruiting
NCT07038519
1,305 pts·Bladder Ca
2021-10→TBD·Completed
2,245 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-254.2y awayPh2 Data· Bladder Ca
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Not yet…
P1/2
Complet…
Catalysts
Ph2 Data
2030-05-25 · 4.2y away
Bladder Ca
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06751063 | Phase 1/2 | Bladder Ca | Not yet recr... | 940 | CR |
| NCT07038519 | Phase 1/2 | Bladder Ca | Completed | 1305 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK |